1
|
Pàmpols T, Ramos FJ, Lapunzina P, Gozalo‐Salellas I, Pérez‐Jurado LA, Pujol A. A view on clinical genetics and genomics in Spain: of challenges and opportunities. Mol Genet Genomic Med 2016; 4:376-91. [PMID: 27468414 PMCID: PMC4947857 DOI: 10.1002/mgg3.232] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A view on clinical genetics and genomics in Spain: of challenges and opportunities.
Collapse
Affiliation(s)
- Teresa Pàmpols
- Division of Inborn Errors of MetabolismDepartment of Biochemistry and Molecular GeneticsHospital ClinicBarcelonaSpain
- Center for Biomedical Research on Rare Diseases CIBERER U737BarcelonaSpain
| | - Feliciano J. Ramos
- Unit of Clinical GeneticsService of PediatricsUniversity Hospital “Lozano Blesa”ZaragozaSpain
- Functional GenomicsDepartment PediatricsUniversity of Zaragoza Medical SchoolZaragozaSpain
- Center for Biomedical Research on Rare Diseases CIBERER‐GCV02ZaragozaSpain
| | - Pablo Lapunzina
- Clinical Genetics UnitInstitute of Medical and Molecular Genetics (INGEMM)IdiPAZHospital Universitario La PazMadridSpain
- Center for Biomedical Research on Rare Diseases CIBERER U753MadridSpain
| | - Ignasi Gozalo‐Salellas
- Department of Romance LanguagesUniversity of Pennsylvania521 Williams Hall 255 S. 36th StreetPhiladelphiaPennsylvania19104
| | - Luis A. Pérez‐Jurado
- Genetics UnitDepartment of Experimental and Health SciencesPompeu Fabra University (UPF)BarcelonaSpain
- Hospital del Mar Research Institute (IMIM)BarcelonaSpain
- Center for Biomedical Research on Rare Diseases CIBERER U735BarcelonaSpain
| | - Aurora Pujol
- Neurometabolic Diseases LaboratoryInstitute of NeuropathologyIDIBELLBarcelonaSpain
- Center for Biomedical Research on Rare Diseases CIBERER U759BarcelonaSpain
- Catalan Institution of Research and Advanced Studies (ICREA)BarcelonaSpain
| |
Collapse
|
2
|
Fourcade S, Ruiz M, Camps C, Schlüter A, Houten SM, Mooyer PAW, Pàmpols T, Dacremont G, Wanders RJA, Giròs M, Pujol A. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 2009; 296:E211-21. [PMID: 18854420 DOI: 10.1152/ajpendo.90736.2008] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Peroxisomes are essential organelles exerting key functions in fatty acid metabolism such as the degradation of very long-chain fatty acids (VLCFAs). VLCFAs accumulate in X-adrenoleukodystrophy (X-ALD), a disease caused by deficiency of the Abcd1 peroxisomal transporter. Its closest homologue, Abcd2, exhibits a high degree of functional redundancy on the catabolism of VLCFA, being able to prevent X-ALD-related neurodegeneration in the mouse. In the search for specific roles of Abcd2, we screened fatty acid profiles in organs and primary neurons of mutant knockout mice lacking Abcd2 in basal conditions and under dietary challenges. Our results indicate that ABCD2 plays a role in the degradation of long-chain saturated and omega9-monounsaturated fatty acids and in the synthesis of docosahexanoic acid (DHA). Also, we demonstrated a defective VLCFA beta-oxidation ex vivo in brain slices of Abcd1 and Abcd2 knockouts, using radiolabeled hexacosanoic acid and the precursor of DHA as substrates. As DHA levels are inversely correlated with the incidence of Alzheimer's and several degenerative conditions, we suggest that ABCD2 may act as modulator/modifier gene and therapeutic target in rare and common human disorders.
Collapse
Affiliation(s)
- Stéphane Fourcade
- Centre de Genètica Mèdica i Molecular, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Arias A, Corbella M, Fons C, Sempere A, García-Villoria J, Ormazabal A, Poo P, Pineda M, Vilaseca MA, Campistol J, Briones P, Pàmpols T, Salomons GS, Ribes A, Artuch R. Creatine transporter deficiency: Prevalence among patients with mental retardation and pitfalls in metabolite screening. Clin Biochem 2007; 40:1328-31. [PMID: 17825809 DOI: 10.1016/j.clinbiochem.2007.07.010] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2007] [Revised: 06/10/2007] [Accepted: 07/02/2007] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To report the prevalence of creatine transporter deficiency in males with mental retardation and to study whether a protein-rich food intake might be a potential diagnostic pitfall. DESIGN AND METHODS We determined creatine/creatinine ratio in urine samples from 1600 unrelated male patients with mental retardation and/or autism. Urine creatine was analyzed by HPLC-MS/MS. RESULTS Thirty-three of 1600 cases showed increased urine creatine/creatinine ratio. Four out of these thirty-three cases were definitively diagnosed with creatine transporter deficiency, while the other 29 were false positive results. Significantly higher values were observed for urine Cr/Crn ratio in healthy volunteers after a meal based on beef or oily fish as compared to eggs, pasta or salad (Wilcoxon test: p<0.005). CONCLUSIONS False positive results may be observed in biochemical screening for creatine transporter deficiency, and they may be due to intake of meals rich in creatine prior to urine samples analysis.
Collapse
Affiliation(s)
- Angela Arias
- Institut de Bioquímica Clínica, Servicio de Bioquímica y Genética Molecular, Hospital Clínic and Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Arias A, Ormazabal A, Moreno J, González B, Vilaseca MA, García-Villoria J, Pàmpols T, Briones P, Artuch R, Ribes A. Methods for the diagnosis of creatine deficiency syndromes: A comparative study. J Neurosci Methods 2006; 156:305-9. [PMID: 16621013 DOI: 10.1016/j.jneumeth.2006.03.005] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2005] [Revised: 03/07/2006] [Accepted: 03/08/2006] [Indexed: 11/22/2022]
Abstract
The increasing number of patients with creatine deficiency syndromes (CDS) stresses the need to develop screening procedures for the identification these inherited disorders. Guanidinoacetate (GAA) and creatine (Cr) are reliable biochemical markers of CDS and several analytical methods to measure both metabolites have been developed. High-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) is quick and sensitive but, unlike HPLC and gas chromatography-mass spectrometry (GC/MS), it is unavailable in most laboratories. Thus, we decided to evaluate comparatively HPLC-MS/MS, GC/MS and HPLC methods, as well as to establish reference values in a healthy paediatric population. According to our results, these three methods may be suitable for analysing GAA in urine. Furthermore, Passing-Bablock plots showed good agreement among all three. However, when comparing the Cr/Crn ratio, our results revealed that while HPLC-MS/MS data were in agreement with those of GC/MS, a constant and proportional error was observed when compared with those of HPLC. Consequently, the Cr/Crn ratio obtained by the last method should be evaluated with caution. Our reference values for GAA and Cr/Crn ratio in urine negatively correlate with age. Concerning GAA and Cr measurements in plasma, it is interesting to note that in contrast to what was occurring in urine, GAA concentration increased significantly with age, while we did not find any significant difference for Cr values within the same age group.
Collapse
Affiliation(s)
- Angela Arias
- Servei de Bioquímica, Hospital Sant Joan de Déu, Esplugues, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Coll MJ, Palau N, Camps C, Ruiz M, Pàmpols T, Girós M. X-linked adrenoleukodystrophy in Spain. Identification of 26 novel mutations in the ABCD1 gene in 80 patients. Improvement of genetic counseling in 162 relative females. Clin Genet 2005; 67:418-24. [PMID: 15811009 DOI: 10.1111/j.1399-0004.2005.00423.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In this study, we analyzed the ABCD1 gene in 80 X-linked adrenoleukodystrophy (X-ALD) patients from 62 unrelated families. We identified 53 different mutations, of which 26 are novel and two are non-pathogenic sequence variants (L516L and 3'UTR, 2246C/G) that have been previously described. The Spanish population had significant allelic heterogeneity, in which most of the mutations were exclusive to a single family 47/53 (88.7%). Only six mutations (Y174S, G277R, FsE471, R518Q, P543L, and R554H) were found in more than one family. Mutations G277R, P543L, and R554H were the most frequent, each of them being found in three patients (5%). Intra-familiar phenotype variability was observed in most of the families, but in one, with the novel mutation R120P, only the adult mild phenotype was present (five hemizygous family members). We detected 80 heterozygous women by mutation analysis, but only 78 of them showed increased very-long-chain fatty acid levels. In conclusion, this study extends the spectrum of mutations in X-ALD and facilitates the identification of heterozygous females. Our results are also consistent with previous studies reporting the difficulty of predicting genotype-phenotype correlation.
Collapse
Affiliation(s)
- M J Coll
- Institut de Bioquímica Clínica, Corporació Sanitària Clinic, C/Mejía Lequerica s/n. Edificio Helios III, 08028 Barcelona, Spain.
| | | | | | | | | | | |
Collapse
|
6
|
Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pàmpols T, Giròs M, Mandel JL. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 2004; 13:2997-3006. [PMID: 15489218 DOI: 10.1093/hmg/ddh323] [Citation(s) in RCA: 152] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disease caused by loss of function of the peroxisomal transporter ABCD1 (ALD), which results in accumulation of very long chain fatty acids (VLCFAs) in organs and serum, central demyelination and peripheral axonopathy and Addison's disease. Knockout of the ALD gene in the mouse (ALD(-)) results in an adrenomyeloneuropathy-like disease (a late onset form of X-ALD). In the present study, we demonstrate that axonal damage occurs as first pathological event in this model, followed by myelin degeneration. We show that this phenotype can be modulated through expression levels of an ALD-related gene (ALDR/ABCD2), its closest paralogue and a target of PPARalpha and SREBP transcription factors. Overexpression of ALDR in ALD(-) mice prevents both VLCFAs accumulation and the neurodegenerative features, whereas double mutants for ALD and ALDR exhibit an earlier onset and more severe disease (including signs of inflammatory reaction) when compared with ALD single mutants. Thus, our results provide direct evidence for functional redundancy/overlap between both transporters in vivo and highlight ALDR as therapeutic target for treatment of X-ALD.
Collapse
Affiliation(s)
- Aurora Pujol
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM.ULP and Collè de France. Illkirch, CU de Strasbourg, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Pàmpols T. Neonatal screening. Turk J Pediatr 2003; 45:87-94. [PMID: 12921292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Neonatal screening (NS) is a medical act in the context of preventive medicine aimed at the early identification of infants affected by certain conditions that threaten their life and long-term health, for which a timely intervention can lead to a significant reduction of morbidity, mortality and associated disabilities. It emerged three decades ago in the context of prevention of mental retardation. Since then, around 600 inborn metabolic disorders have been described and technological progress has been impressive; nevertheless only around 5% of the disorders have been the object of NS. The most frequently cited reasons for the limitation are low prevalence and the lack of treatment. The tandem mass spectrometry has come in place in recent years across the globe, expanding NS to include several disorders of intermediary metabolism. This has shown, in addition to a prevalence much higher than previously thought, the benefits of early detection. The present work is a review of NS, not only from the point of view of technological/medical achievements, but also considering other factors which will affect specific disease selection, according to the social and organizational infrastructure that may expand the borders of NS.
Collapse
Affiliation(s)
- Teresa Pàmpols
- Institut de Bioquimica Clinica, Clinic Corporaciò Sanitària, Barcelona, Spain
| |
Collapse
|
8
|
Rifé M, Mallolas J, Badenas C, Tazón B, Miguélez MR, Pàmpols T, Sànchez A, Milà M. Pilot study for the neonatal screening of fragile X syndrome. Prenat Diagn 2002; 22:459-62. [PMID: 12116303 DOI: 10.1002/pd.346] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Fragile X syndrome (SFX) is the commonest form of inherited mental retardation. Due to the highly variable phenotype clinical diagnosis is complicated. In nearly all cases, the disorder is caused by expansion of a CGG-repeat in the 5'-untranslated region of the FMR1 (fragile X mental retardation-1) gene. We have evaluated the feasibility, efficiency and costs of two methodologies in order to develop a simple test to screen large populations: PCR and fragile X mental retardation-1 protein (FMRP) immunodetection. We studied 100 newborn males using PCR and immunodetection (26.91 Euro). All but one amplified the CGG repeat of the FMR1 gene within the normal size range. The sample that failed to amplify showed only 28% of FMRP expression by immunodetection study; both results indicated an affected male. A further 100 males were studied only by polymerase chain reaction (PCR) (7.8 Euro); all of them amplified within the normal size range. Both methodologies, PCR and immunodetection, are feasible for screening large populations, PCR being the most suitable, economical and less time-consuming. However, it is advisable to keep slides for immunodetection when PCR fails or the external control shows no amplification. Early detection of SFX-affected individuals would represent a great benefit for their maximum social integration, due to appropriate treatment and early stimulation and would permit a cascade screening in their pedigree.
Collapse
Affiliation(s)
- M Rifé
- Genetics Service, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Girós M, Ruiz M, Ribes A, Pàmpols T. [The diagnosis of peroxisomal disorders in Spain during the period 1987-1997]. Rev Neurol 1999; 28 Suppl 1:S40-4. [PMID: 10778487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
INTRODUCTION Peroxisomal disorders are divided into two groups: a) Those with alterations in multiple peroxisomal functions, and b) With alterations in only one peroxisomal function. DEVELOPMENT During the period 1987-1997, using very long chain fatty acids, plasmalogens and phytanic acid as diagnostic parameters, we diagnosed 116 cases of peroxisomal disorders in Spain. The most frequent (76%) was found to be X-linked adrenoleukodystrophy (X-ALD). Of the five phenotypes described in this condition, the adult cerebral form is seen in a higher percentage in the Spanish population (14%) than in other populations studied (1-3%). Defects in the assembly of peroxisomes made up 18%; the commonest phenotype was that of Zellweger's syndrome (13 cases), followed by neonatal adrenoleukodystrophy (5 cases) and infantile Refsum (2 cases). In the latter two patients, study of the hepatic peroxisomes showed a mosaic distribution. Rhizomelic punctate chondroplasia made up 3%, isolated beta-oxidation defects 2% and defects of plasmalogen synthesis 1%. In X-ALD, diagnosis of an initial case led to the detection of 12 presymptomatic and 70 heterozygote persons. Prenatal diagnoses were made on 10 occasions and 7 fetuses found to be affected. The introduction of the study of ALDP expression in the fibroblasts and the profile of the organic acids in the urine has led to improved diagnosis of these disorders.
Collapse
Affiliation(s)
- M Girós
- Institut de Bioquímica Clínica, Barcelona.
| | | | | | | |
Collapse
|
10
|
Pàmpols T, Pineda M, Girós ML, Ferrer I, Cusi V, Chabás A, Sanmarti FX, Vanier MT, Christomanou H. Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant. Acta Neuropathol 1999; 97:91-7. [PMID: 9930900 DOI: 10.1007/s004010050960] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Glucosylceramide lipidosis results from a defective lysosomal degradation of this glycolipid. Lipid degradation is controlled by two components, the enzyme beta-glucocerebrosidase and a sphingolipid activator protein. While most Gaucher cases are due to mutations within the gene that codes for the lysosomal enzyme, only two patients have been described with normal enzyme levels and mutations in the gene for the sphingolipid activator protein C (sap-C). Here we present the detailed neurological manifestations, neuropathological findings and brain lipid composition in one sap-C-deficient patient. The patient was an 8-year-old boy who presented with transient losses of consciousness, myoclonic jerks and generalized seizures resistant to all antiepileptic drugs. He developed progressive horizontal ophthalmoplegia, pyramidal and cerebellar signs, and died at the age of 15.5 years. Neuropathological studies demonstrated neuronal cell loss and neuronophagia, massive intraneuronal lipid storage and lack of perivascular Gaucher cells. Electron microscopy examination showed different types of storage including lipofuscin granules as well as the cytosomes with parallel arrays of bilayers that are assumed to be formed by stored lipids. General brain lipid composition did not show a remarkable increase or loss of any of the major lipid fractions but the glucosylceramide concentration in the cortex of several anatomical regions showed a striking increase. Fatty acid composition of the ceramide moiety clearly suggests that gangliosides are the main precursors in the cerebral cortex, while it implies an additional and distinct source in the cerebellum. Studying the phenotypic consequences of mutant sphingolipid activator proteins is critical to a better understanding of the physiological significance of these proteins.
Collapse
Affiliation(s)
- T Pàmpols
- Institut de Bioquímica clínica, Corporació Sanitària, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disorder caused by an impairment in peroxisomal beta-oxidation of very long straight-chain fatty acids (VLCFAs). Six clinical phenotypes have been delineated: childhood cerebral (CCALD), adolescent cerebral (AdolCALD), adult cerebral (ACALD), adrenomyeloneuropathy (AMN), Addison-only (AO), and presymptomatic (PALD). The distribution of phenotypes varies in different countries. We have diagnosed biochemically 60 X-ALD Spanish patients belonging to 48 kindreds. Their phenotypic distribution was: CCALD plus AdolCALD, 33%; ACALD, 16%; AMN, 27%; AO, 12%; and PALD, 12%. These results contrast with the distribution described in other countries, due to a higher prevalence of the ACALD form. Regarding the expression of the protein product (ALDP), we studied 17 kindreds using immunochemical techniques and found absence of ALDP in 84% of cases. We also studied 13 females from 7 negative ALDP kindreds in order to correlate ALDP expression and the carrier status established by VLCFA measurement. In one case with normal VLCFA levels in serum and fibroblasts, we observed mosaicism in ALDP expression. This fact supports the use of this technique for identifying carriers.
Collapse
Affiliation(s)
- M Ruiz
- Institut de Bioquímica Clínica, Barcelona, Spain
| | | | | | | |
Collapse
|
12
|
Roels F, Tytgat T, Beken S, Giros M, Espeel M, De Prest B, Kerckaert I, Pàmpols T, Rogiers V. Peroxisome mosaics in the liver of patients and the regulation of peroxisome expression in rat hepatocyte cultures. Ann N Y Acad Sci 1996; 804:502-15. [PMID: 8993568 DOI: 10.1111/j.1749-6632.1996.tb18640.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- F Roels
- Department of Human Anatomy, Embryology and Histology, University of Gent, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Barceló A, Girós M, Albiach V, Vaquerizo J, Pàmpols T, Estivill X. Identification of two new nonsense mutations Q311X and W326X in Exon 2 of the adrenoleukodystrophy (ALD) gene. Hum Mutat 1996. [DOI: 10.1002/(sici)1098-1004(1996)8:3<286::aid-humu17>3.3.co;2-j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
14
|
Affiliation(s)
- A Barceló
- Servei de Genètica, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
15
|
Barceló A, Girós M, Sarde CO, Pintos G, Mandel JL, Pàmpols T, Estivill X. De novo missense mutation Y174S in exon 1 of the adrenoleukodystrophy (ALD) gene. Hum Genet 1995; 95:235-7. [PMID: 7860075 DOI: 10.1007/bf00209412] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Adrenoleukodystrophy (ALD) is an X-linked disease, characterised by an alteration of the peroxisomal beta-oxidation of the very long chain fatty acids. The ALD gene has been identified and mutations have been detected in ALD patients. We report here a new missense mutation in the ALD gene of a male patient, predicting a tyrosine to serine substitution at codon 174 (mutation Y174S). The mother of the ALD patient does not have the Y174S mutation in her leukocyte DNA, indicating that Y174S arose de novo in the patient. Y174S is the first reported de novo mutation in the ALD gene.
Collapse
Affiliation(s)
- A Barceló
- Servei de Genètica, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
16
|
Barceló A, Girós M, Sarde CO, Martínez-Bermejo A, Mandel JL, Pàmpols T, Estivill X. Identification of a new frameshift mutation (1801delAG) in the ALD gene. Hum Mol Genet 1994; 3:1889-90. [PMID: 7849718 DOI: 10.1093/hmg/3.10.1889] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Affiliation(s)
- A Barceló
- Servei de Genètica, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|